Abstract
Retinoic acid (RA) is a chemotherapeutic agent used to induce neuronal cellular differentiation of neuroblastoma. However, because treatment with RA is associated with the side-effect of nyctalopia, efforts have been underway to identify new compounds that could potentially overcome these drawbacks. As part of these studies we have examined anti-cancer effects on the neuroblastoma NB-39-nu cells of p-dodecylaminophenol (p-DDAP), a novel derivative of N-(4-hydroxyphenyl) retinamide (4-HPR). p-DDAP suppresses proliferation, and induces G0/G1 arrest and apoptosis to a greater extent than RA and 4-HPR. Neuronal differentiation was not detected in p-DDAP-treated cells. Since p-DDAP is not toxic and does not reduce blood retinol levels, p-DDAP might be a useful anti-neuroblastoma drug having reduced side-effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
